Mast Therapeutics subsidiary advances trial for inhaled sodium nitrite solution

Mast Therapeutics (NYSE:MSTX) said today that its subsidiary Aires Pharmaceuticals inked a deal with the University of Pittsburgh related to its phase 1/2 open-label proof-of-concept trial for the company’s AIR001 inhaled sodium nitrite solution in patients with cystic fibrosis.

The study will evaluate the nebulized drug as a treatment of Pseudomonas aeruginosa infection in CF patients, according to Mast. The subsidiary plans to provide the drug and nebulizers for the study, but no financial support.

Get the full story at our sister site, Drug Delivery Business News.

The post Mast Therapeutics subsidiary advances trial for inhaled sodium nitrite solution appeared first on MassDevice.

from MassDevice http://ift.tt/2mudpTW